Oelkrug Christopher
Advanced Clinical, Frankfurt, Germany.
Clin Exp Vaccine Res. 2024 Apr;13(2):73-82. doi: 10.7774/cevr.2024.13.2.73. Epub 2024 Apr 30.
DNA cancer vaccines as an approach in tumor immunotherapy are still being investigated in preclinical and clinical settings. Nevertheless, only a small number of clinical studies have been published so far and are still active. The investigated vaccines show a relatively stable expression in transfected cells and may be favorable for developing an immunologic memory in patients. Therefore, DNA vaccines could be suitable as a prophylactic or therapeutic approach against cancer. Due to the low efficiency of these vaccines, the administration technique plays an important role in the vaccine design and its efficacy. These DNA cancer vaccine delivery systems include physical, biological, and non-biological techniques. Although the pre-clinical studies show promising results in the application of the different delivery systems, further studies in clinical trials have not yet been successfully proven.
DNA癌症疫苗作为肿瘤免疫治疗的一种方法仍处于临床前和临床研究阶段。然而，到目前为止，仅有少数临床研究发表且仍在进行中。所研究的疫苗在转染细胞中表现出相对稳定的表达，可能有利于在患者体内形成免疫记忆。因此，DNA疫苗可能适合作为预防或治疗癌症的方法。由于这些疫苗效率较低，给药技术在疫苗设计及其疗效方面起着重要作用。这些DNA癌症疫苗递送系统包括物理、生物和非生物技术。尽管临床前研究表明不同递送系统的应用前景良好，但在临床试验中的进一步研究尚未得到成功验证。
